Literature DB >> 10745183

Refining a measure of brain injury sequelae to predict postacute rehabilitation outcome: rating scale analysis of the Mayo-Portland Adaptability Inventory.

J F Malec1, A M Moessner, M Kragness, M D Lezak.   

Abstract

OBJECTIVE: Evaluate the psychometric properties of the Mayo-Portland Adaptability Inventory (MPAI).
DESIGN: Rating scale (Rasch) analysis of MPAI and principal component analysis of residuals; the predictive validity of the MPAI measures and raw scores was assessed in a sample from a day rehabilitation program.
SETTING: Outpatient brain injury rehabilitation. PARTICIPANTS: 305 persons with brain injury.
RESULTS: A 22-item scale reflecting severity of sequelae of brain injury that contained a mix of indicators of impairment, activity, and participation was identified. Scores and measures for MPAI scales were strongly correlated and their predictive validities were comparable.
CONCLUSIONS: Impairment, activity, and participation define a single dimension of brain injury sequelae. The MPAI shows promise as a measure of this construct.

Entities:  

Mesh:

Year:  2000        PMID: 10745183     DOI: 10.1097/00001199-200002000-00006

Source DB:  PubMed          Journal:  J Head Trauma Rehabil        ISSN: 0885-9701            Impact factor:   2.710


  13 in total

1.  Post-Inpatient Brain Injury Rehabilitation Outcomes: Report from the National OutcomeInfo Database.

Authors:  James F Malec; Jacob Kean
Journal:  J Neurotrauma       Date:  2015-11-19       Impact factor: 5.269

2.  [Item response theory and its application in neurology. Measurement of activity limitations in neurologic patients].

Authors:  S Gauggel; M Böcker; P Zimmermann; C Privou; D Lutz
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

3.  Group Differences Among Caregivers of Civilians and Service Members or Veterans With Traumatic Brain Injury.

Authors:  Eva Keatley; Robin Hanks; Angelle M Sander; Anna L Kratz; David S Tulsky; Phillip Ianni; Jennifer Miner; Noelle E Carlozzi
Journal:  Arch Phys Med Rehabil       Date:  2018-12-08       Impact factor: 3.966

4.  The Minimal Clinically Important Difference for the Mayo-Portland Adaptability Inventory.

Authors:  James F Malec; Jacob Kean; Patrick O Monahan
Journal:  J Head Trauma Rehabil       Date:  2017 Jul/Aug       Impact factor: 2.710

5.  Rasch measurement analysis of the Mayo-Portland Adaptability Inventory (MPAI-4) in a community-based rehabilitation sample.

Authors:  Jacob Kean; James F Malec; Irwin M Altman; Shannon Swick
Journal:  J Neurotrauma       Date:  2011-04-12       Impact factor: 5.269

6.  An exploratory analysis of functional staging using an item response theory approach.

Authors:  Wei Tao; Stephen M Haley; Wendy J Coster; Pengsheng Ni; Alan M Jette
Journal:  Arch Phys Med Rehabil       Date:  2008-06       Impact factor: 3.966

7.  Development and psychometric properties of the Carer - Head Injury Neurobehavioral Assessment Scale (C-HINAS) and the Carer - Head Injury Participation Scale (C-HIPS): patient and family determined outcome scales.

Authors:  Shoumitro Deb; Eleanor Bryant; Paul G Morris; Lindsay Prior; Glyn Lewis; Sayeed Haque
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

8.  Development and psychometric properties of the Patient-Head Injury Participation Scale (P-HIPS) and the Patient-Head Injury Neurobehavioral Assessment Scale (P-HINAS): patient and family determined outcomes scales.

Authors:  Shoumitro Deb; Eleanor Bryant; Paul G Morris; Lindsay Prior; Glyn Lewis; Sayeed Haque
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

9.  Rehabilitation Outcomes: Ischemic versus Hemorrhagic Strokes.

Authors:  Robert Perna; Jessica Temple
Journal:  Behav Neurol       Date:  2015-07-12       Impact factor: 3.342

10.  Detection of Growth Hormone Deficiency in Adults with Chronic Traumatic Brain Injury.

Authors:  Lisa A Kreber; Grace S Griesbach; Mark J Ashley
Journal:  J Neurotrauma       Date:  2015-11-19       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.